No Data
No Data
Express News | Chengdu Pioneer collaborated with Pfizer to develop an isoquinolone skeleton synthesis method suitable for DEL
Chengdu Pioneer (688222): DEL core business significantly resumed diversified characteristic platforms to accelerate commercialization
Incident: On April 24, 2024, Chengdu Pioneer released its 2023 annual report. The company achieved annual revenue of 371 million yuan, an increase of 12.64% over the previous year; net profit to mother was 407.18,500 yuan, an increase of 61.
Minsheng Securities released a research report on April 25 stating that it gave Chengdu Xiandao (688222.SH) a recommended rating. The main reasons for the rating include: 1) the DEL screening and library customization business has recovered significantly,
Minsheng Securities released a research report on April 25 stating that it gave Chengdu Xiandao (688222.SH) a recommended rating. The main reasons for the rating include: 1) the DEL screening and library customization business has recovered significantly, continuously improving novelty and service diversification; 2) the diversified technology platform gradually shows commercial value and strengthens the company's new drug discovery and optimization capabilities; 3) R&D investment focuses on platform upgrades and iterations and key pipelines, and AI accelerates the efficiency of drug development. (Mainichi Keizai Shimbun)
Chengdu Pioneer (688222.SH) announced its 2023 annual results, with net profit of 40.72 million yuan, an increase of 61.16% over the previous year
Chengdu Pioneer (688222.SH) disclosed its 2023 annual report, and the company achieved revenue of 3 in 2023...
The A-share CRO sector collectively rebounded, and Xuantai Pharmaceutical rose more than 15%
Gelonghui, April 17 | Xuantai Pharmaceutical rose more than 15%, while stocks such as Yuanbio, Chengdu Pioneer, Wisdom Pharmaceuticals, Haite Biotech, and Baihua Pharmaceuticals rose more than 5%. According to the news, Xuantai Pharmaceutical predicts a 201% year-on-year increase in net profit for the first quarter. In addition, Frost & Sullivan predicts that the global CRO market is expected to be about 96 billion US dollars in 2024, of which the segmented clinical CRO market accounts for the largest share, accounting for about 64% in 2022, the market size is about 51.4 billion US dollars, and is expected to grow to 62.2 billion US dollars in 2024. Furthermore, China's CRO market is growing faster than the global market.
Are HitGen Inc.'s (SHSE:688222) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at HitGen's (SHSE:688222) recent performance, when its stock has declined 22% over the past three months. It seems that the market might have completely ignor
No Data